Literature DB >> 21867402

Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.

Eleazar Soto1, Roberto Romero, Juan Pedro Kusanovic, Giovanna Ogge, Youssef Hussein, Lami Yeo, Sonia S Hassan, Chong Jai Kim, Tinnakorn Chaiworapongsa.   

Abstract

OBJECTIVE: An imbalance between maternal angiogenic/anti-angiogenic factors concentrations has been observed in preeclampsia (PE) and other obstetrical syndromes. However, the frequency of pathologic findings in the placenta and the changes in maternal plasma angiogenic/anti-angiogenic factor concentrations differ between late- and early-onset PE. The aim of this study was to determine if the maternal plasma concentrations of placental growth factor (PlGF), soluble endoglin (sEng), and soluble vascular endothelial growth factor receptor-1 and 2 (sVEGFR-1 and sVEGFR-2) are different in late-onset PE with and without placental pathologic findings consistent with maternal underperfusion. STUDY
DESIGN: A cross-sectional study was conducted including 64 uncomplicated women and 66 women with late-onset PE (>34 weeks) who had blood samples and placenta available for pathologic examination. Patients with late-onset PE were divided into those with and without placental histologic findings consistent with maternal underperfusion as proposed by the Society for Pediatric Pathology. Maternal plasma concentrations of PlGF, sEng, sVEGFR-1 and sVEGRF-2 were determined by ELISA. Non-parametric statistics were used for analysis.
RESULTS: 1) the prevalence of placental histological findings consistent with maternal underperfusion among women with late-onset PE was higher than that of those with an uncomplicated pregnancy (47% (31/66) vs. 7.8% (5/64), respectively; p < 0.01); 2) patients with late-onset PE and histological findings consistent with maternal underperfusion had a significantly lower median plasma concentration of PlGF, plasma PlGF/sVEGFR-1 ratio and plasma PlGF/sEng ratio than those with late-onset PE without placental underperfusion lesions (each p < 0.05); 3) the most common pathological findings in the placenta of patient with PE were lesions consistent with villous changes (77%, 24/31); and 4) isolated vascular lesions in the placenta were found only in 2 cases (6.5%), and the rest had a combination of villous and vascular lesions.
CONCLUSIONS: Nearly half of the patients with late-onset PE have placental lesions consistent with maternal underperfusion. These lesions are associated with an imbalance in the maternal concentration of angiogenic/anti-angiogenic factors. We propose that there is a link between maternal underperfusion and an anti-angiogenic state characterized by the changes in the concentrations of angiogenic and anti-angiogenic factors in women with late onset PE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21867402      PMCID: PMC3401571          DOI: 10.3109/14767058.2011.591461

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  150 in total

1.  Are early and late preeclampsia distinct subclasses of the disease--what does the placenta reveal?

Authors:  J L van der Merwe; D R Hall; C Wright; P Schubert; D Grové
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

2.  Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia.

Authors:  Lars J Vatten; Anne Eskild; Tom I L Nilsen; Stig Jeansson; Pål A Jenum; Anne Cathrine Staff
Journal:  Am J Obstet Gynecol       Date:  2007-03       Impact factor: 8.661

3.  Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women.

Authors:  M Muy-Rivera; S Vadachkoria; G B Woelk; C Qiu; K Mahomed; M A Williams
Journal:  Physiol Res       Date:  2005       Impact factor: 1.881

4.  Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction.

Authors:  D Schlembach; W Wallner; R Sengenberger; E Stiegler; M Mörtl; M W Beckmann; U Lang
Journal:  Ultrasound Obstet Gynecol       Date:  2007-04       Impact factor: 7.299

5.  Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature.

Authors:  Thomas Walther; Gerd Wallukat; Alexander Jank; Sabine Bartel; Heinz-Peter Schultheiss; Renaldo Faber; Holger Stepan
Journal:  Hypertension       Date:  2005-10-31       Impact factor: 10.190

6.  Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia.

Authors:  H Masuyama; T Segawa; Y Sumida; A Masumoto; S Inoue; Y Akahori; Y Hiramatsu
Journal:  BJOG       Date:  2009-12-10       Impact factor: 6.531

7.  Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats.

Authors:  Mona Sedeek; Jeffrey S Gilbert; Babbette B LaMarca; Myssara Sholook; Derrick L Chandler; Yuping Wang; Joey P Granger
Journal:  Am J Hypertens       Date:  2008-07-31       Impact factor: 2.689

8.  Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction.

Authors:  Fàtima Crispi; Carmen Domínguez; Elisa Llurba; Pilar Martín-Gallán; Luís Cabero; Eduard Gratacós
Journal:  Am J Obstet Gynecol       Date:  2006-03-20       Impact factor: 8.661

9.  Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation.

Authors:  B Huppertz; J Kingdom; I Caniggia; G Desoye; S Black; H Korr; P Kaufmann
Journal:  Placenta       Date:  2003 Feb-Mar       Impact factor: 3.481

10.  Hypertensive disorders and severe obstetric morbidity in the United States.

Authors:  Elena V Kuklina; Carma Ayala; William M Callaghan
Journal:  Obstet Gynecol       Date:  2009-06       Impact factor: 7.661

View more
  54 in total

1.  Is an episode of suspected preterm labor that subsequently leads to a term delivery benign?

Authors:  Roberto Romero; Offer Erez; Eli Maymon; Percy Pacora
Journal:  Am J Obstet Gynecol       Date:  2017-02       Impact factor: 8.661

Review 2.  Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.

Authors:  Roberto Romero; Offer Erez; Maik Hüttemann; Eli Maymon; Bogdan Panaitescu; Agustin Conde-Agudelo; Percy Pacora; Bo Hyun Yoon; Lawrence I Grossman
Journal:  Am J Obstet Gynecol       Date:  2017-06-12       Impact factor: 8.661

3.  Prenatal diagnosis of a placental infarction hematoma associated with fetal growth restriction, preeclampsia and fetal death: clinicopathological correlation.

Authors:  Alma Aurioles-Garibay; Edgar Hernandez-Andrade; Roberto Romero; Faisal Qureshi; Hyunyoung Ahn; Suzanne M Jacques; Maynor Garcia; Lami Yeo; Sonia S Hassan
Journal:  Fetal Diagn Ther       Date:  2014-05-17       Impact factor: 2.587

Review 4.  Anti-angiogenesis and Preeclampsia in 2016.

Authors:  Susanne Schrey-Petersen; Holger Stepan
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 5.  Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis.

Authors:  Kathryn J Gray; Richa Saxena; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2017-11-11       Impact factor: 8.661

Review 6.  Role of decidual natural killer cells, interleukin-15, and interferon-γ in placental development and preeclampsia.

Authors:  Jenny L Sones; Heinrich E Lob; Catherine E Isroff; Robin L Davisson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-11       Impact factor: 3.619

7.  Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Authors:  Nandor Gabor Than; Roberto Romero; Adi Laurentiu Tarca; Katalin Adrienna Kekesi; Yi Xu; Zhonghui Xu; Kata Juhasz; Gaurav Bhatti; Ron Joshua Leavitt; Zsolt Gelencser; Janos Palhalmi; Tzu Hung Chung; Balazs Andras Gyorffy; Laszlo Orosz; Amanda Demeter; Anett Szecsi; Eva Hunyadi-Gulyas; Zsuzsanna Darula; Attila Simor; Katalin Eder; Szilvia Szabo; Vanessa Topping; Haidy El-Azzamy; Christopher LaJeunesse; Andrea Balogh; Gabor Szalai; Susan Land; Olga Torok; Zhong Dong; Ilona Kovalszky; Andras Falus; Hamutal Meiri; Sorin Draghici; Sonia S Hassan; Tinnakorn Chaiworapongsa; Manuel Krispin; Martin Knöfler; Offer Erez; Graham J Burton; Chong Jai Kim; Gabor Juhasz; Zoltan Papp
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

8.  Stillbirth, hypertensive disorders of pregnancy, and placental pathology.

Authors:  Karen J Gibbins; Robert M Silver; Halit Pinar; Uma M Reddy; Corette B Parker; Vanessa Thorsten; Marian Willinger; Donald J Dudley; Radek Bukowski; George R Saade; Matthew A Koch; Deborah Conway; Carol J Hogue; Barbara J Stoll; Robert L Goldenberg
Journal:  Placenta       Date:  2016-05-07       Impact factor: 3.481

9.  Placental growth factor: as an early second trimester predictive marker for preeclampsia in normal and high-risk pregnancies in a Turkish population.

Authors:  Necmiye Dover; Hacer C Gulerman; Sevki Celen; Serkan Kahyaoglu; Okan Yenicesu
Journal:  J Obstet Gynaecol India       Date:  2012-11-02

10.  Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death.

Authors:  Amy E Whitten; Roberto Romero; Steven J Korzeniewski; Adi L Tarca; Alyse G Schwartz; Lami Yeo; Zhong Dong; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  Am J Obstet Gynecol       Date:  2013-01-17       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.